Jimmy Bechtel sits down with Mike Hutton of Almac Clinical Technologies to talk about where site burden really starts, and what sponsors can do earlier in study design to reduce it. They dig into the difference between protocol complexity and operational complexity, why fragmented systems and workflows quietly pile friction onto site staff, and what a more connected, site-first approach to trial design actually looks like. Mike also shares the one question he wishes more sponsors would ask sites before finalizing a protocol.
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
Jimmy BechtelHello and welcome to SCRS Talks provided by the Society for Clinical Research Sites. I'm Jimmy Bechtel, the chief site success officer with the Society, and today I'm joined by Mike Hutton who is the director of strategic partnerships and commercialization with Almac Clinical Technologies, here to talk about designing trials with just a little bit less burden for sites, and things that we can do, things we can think about that reduce the burden that we're placing on the research site itself. But Mike, before we jump in, I'd love to hear a little bit about you and maybe learn a little bit about Almac before we talk about today's subject.
Mike HuttonThanks, Jimmy. Hi, my name's Mike, and I've spent over twenty-six years in clinical research mainly at Almac. Prior to that, I was an academic in the UK. so really happy to talk to you guys today. Almac Clinical Technologies provides eClinical services to the industry. We're traditionally known as an IRT company. That's something we've been famous for all the time that I've been with the company. When I started, everything was done on the phone. We were an IVR company, and that was many years ago, and before the, the web really took off, and we had fax machines to send confirmations to sites.
Mike HuttonSo some of your listeners May remember those days. Almac itself we're a CDMO based in Northern Ireland with about seven and a half thousand employees globally, made up of five business units, all really supporting clinical trials from the really exciting discovery element all the way through clinical supplies and packaging and services, all the way through to technology. And so we're really excited to be able to talk with you and actually become part of the SCRS.
Jimmy BechtelThanks, and we're excited as well. It's been great to have Almac as a partner with SCRS, and I'm really excited to talk with you all about this subject sitting at the, the intersection, the crux of oftentimes sponsor and CRO and site relationships and really focusing on being an enabler of that instead of, as we're going to say many times here, a burden for the sites. But when people talk about site burden it does tend to center on what's happening at the site level, particularly when we talk about this within SCRS or with our partners here.
Jimmy BechtelSo do you think the industry is looking at that problem t- too late? And where does the, the issues surrounding burden really start to begin?
Mike HuttonIt's interesting because as I said I've been doing this for over twenty-five years and, working really at the intersection of trial operations, technology, and study execution. and one thing that's become increasingly clear is that while clinical trials have become more complex more sophisticated sites are carrying more operational burden than ever before. What's interesting, I think, is that many of these challenges aren't really caused by the site themselves. They're often results of decisions that have been made much earlier in the study planning process, and that's why I think this conversation is really important.
Mike HuttonIf we want to improve the site experience which I think is all of our shared goal, we have to start looking further upstream and ask how are these trials being designed, coordinated, and delivered-
Jimmy BechtelThat's an excellent point, Mike, and I think it is important that we start at the level, with the boots on the ground. We look at what is challenging them, and we work backwards from there when we're talking about designing these trials. And I know there's an important distinction between protocol complexity and operational complexity. I talk about this a lot. There are some things that are inherent to the diseases and the conditions that we are creating molecules and clinical trials for that are just flat out complicated, and then there is operational complexity and the things that we are asking the sites to do from an execution.
Jimmy BechtelSo maybe can you help expand upon that and walk us through that difference and most importantly, I think, why it matters for how we design and plan our studies?
Mike HuttonAbsolutely. I think protocol complexity and operational complexity they always get grouped together, but they're really not the same thing. as an academic, protocol complexity, that really reflects the scientific design of the study and it can involve many complex eligibility criteria, intricate visit schedules, specialized assessments, and a really adaptive randomization of study designs. And in my time in the industry, I have just seen that complexity has massively increased over time to the point today where I think, protocols are both increasing in complexity and constantly changing during the course of the study.
Mike HuttonBut it's operational complexity. That's what really happens when you try and execute the protocol in the real world at the clinical site, and it's how many systems does someone have to use? how is the data collected? How is the drug supply managed? And also how are those amendments implemented? And also importantly, how the teams communicate when issues arise. I think what's interesting is that with two studies with very similar protocols, while they can feel similar when you're looking at the protocol and complexity they can feel very different at the site operationally.
Mike Huttonone may have relatively straightforward processes which are aligned and intuitive, while the other may require multiple disconnected workflows that create significant friction. and I think the reason this distinction matters is because we don't always have the ability to simplify the science. But we can often have the ability to simplify the way the science is operationalized, and that's where I think we need to focus as an industry moving forward
Jimmy BechtelI couldn't agree more, Mike. It's an excellent perspective and a point I don't think we can say enough. And I think the more... It's one of those things, the, squeaky wheel maybe in these instances, the more that we can talk about, and especially at the site level. And I would argue as well, our support partners level advocate for differentiating between those two things and helping our sponsor and CRO partners understand where those lines are and what we can and cannot solve for, to the point we're both making here. I think it's I think we'll be in a better place with what is continuing to become really a top issue at the site level around protocol complexity
Mike HuttonI absolutely agree And I think one of the key things we have now is, as I said when I started, I mentioned right at the beginning fax machines, telefax. I think particularly now that we have the technology available, that is where we can really focus on making that improvement to the site's ability to deliver these trials effectively, reduce the friction, and importantly therefore increase the key thing, which is not only the sites, but also the patient's experience.
Jimmy Bechtelyes. You make a great point. that ultimately all trickles down to complexity at the patient level as well, and we yeah if we can't rally around site simplicity, then it would be insane for us to not be able to rally around patient centricity, so it's an excellent point. But... Mike, let's expand upon that, right? Technology and supply chain, more patient workflows, study operations. We see part of that problem, the root of this, maybe it's not the, end all be all or the number one reason, but it is definitely a large part of it being executed and planned in silos.
Jimmy BechtelCan you talk a little bit about what that fragmentation actually might cost sites, and what does a more connected approach actually look like?
Mike HuttonFragmentation, as you say, creates friction. But what's friction? And sites encounter that friction every single day. What does that mean as a cost for them? It means Potentially switching between multiple systems, entering similar information more than once, and also, as we all know in the industry, the quality issues you can have associated with that. dealing with conflicting processes. spending valuable time trying to determine who owns an issue when something arises and needs attention, all of which detracts from patient care. It consumes the time and the attention.
Mike Huttonand so for site coordinators and site staff generally, who we know are already stretched thin, this can be obviously incredibly frustrating. Where a more connected approach starts with the understanding really is our site workflow, rather than look at each function independently. instead of asking,"How do we optimize supply?" Or, How do we optimize data collection in isolation?" We should ask how will the site experience this study from start to finish?" When stakeholders collaborate earlier in design processes around the people executing the trial, we can reduce those handoffs, simplify the workflows, and hopefully create a much smoother operational experience.
Mike HuttonI think one of the things that we probably forget in the industry and should focus on is that sites don't experience the study as separate technologies, vendors, processes, et cetera. They experience one trial, which they're focused on, and delivering that trial both for their site, but also for their patients, and I think that's a key element we need to focus on.
Jimmy BechtelI couldn't agree more, Mike. Focusing on the patient really needs to be, to little surprise I would think from anyone listening or to either of us at the the core of what we do, and understanding ultimately how this is going to affect their workflow is part of that. So rallying around that patient point and connecting some of these things in order to make sure that the patient experience is as positive as it can be given the things around the situation that we could probably talk for another 20 minutes on is critical there. So thank you for sharing that Mike, if you could, as we begin to wrap up, change one assumption that sponsor teams commonly make during study planning.
Jimmy BechtelTalk to me about what that might be, and what would you want them to maybe ask sites instead of that assumption?
Mike HuttonI think the assumption I challenge is that if a process is technically possible, it's automatically practical for sites to execute. And I think Sites are incredibly adaptable The staff, the clinicians, we know they are very adaptable. and historically, they are very committed and have found ways to make studies work. But that shouldn't mean That we keep continuing adding complexity without really fully understanding the impact. I think the question I'd love sponsors to ask more often is, what would make this study easier to operate at your site?
Mike HuttonAsk the site staff this. Not whether the protocol can be executed but what would reduce the friction, perhaps simplify the workflows, and make the preparation easier for coordinators, investigators, and as I said, key people at the end, patients alike. Sites bring a perspective that no planning meeting can ever replicate I think the earlier we bring sites into that study design, the more likely we are to create trials that are both scientifically rigorous, but importantly, operationally realistic I think at the end of the day, sites don't wake up wanting simpler technology, different supplies, and a fewer amendments.
Mike HuttonI'm sure they don't... Most site staff don't wake up wishing that. What they want when they come in is the study to run smoothly to be able to focus on the key element which is the patients in front of them. Get those patients through, who we, should not forget are generally ill in those studies. They're wanting to help that. And I think if we can design trials with that goal in mind from the beginning, we have a real opportunity to reduce the burden, importantly, before it even reaches the site
Jimmy BechtelI couldn't have said it better myself, Mike. It's an excellent way, I think, for us to end the conversation. Focus on the sites, focus on the patients, ask them, involve them, engage them, help bring them in to understand, and break down some of those assumptions that you mentioned is the way that all of us should be operating. And frankly, I'll say it, anyone who is not doing that is falling short of really serving the patients that we all- Claim to be serving.
Mike HuttonI think that's very true, and I think, one of the things at Almac that I'm very proud of is that we really do put patient care first, and it's something we all think about. And I think That's critical for our industry, is, at the end of the day, we want trials to be successful. And having worked in this industry for an incredible l- period of time, like most of us probably listening to this as well, we've impacted healthcare greatly. but again, it's all comes down to the patient, and that patient, as we all know, could be us or a family member, and I think that's a key element that I know certainly drives me when I'm working, is that remembering of thinking of that impact that we can all make.
Mike HuttonBut as I'm pushing that back into sites, making sure, as I say their lives are less burdensome. And even further back because, clinical trials, as we said, a much earlier one, are just getting more complex, and they will only, I believe, get more complex with time. And I think anything we can do to reduce that burden, I think perhaps earlier on, so that the end game it's much easier for everybody taking part. I think that's gotta be the key.
Jimmy BechtelThat's exactly right, Mike. Everyone has to play their part and do what's in the best interest of frankly, the patients here, and that includes the sites. That's what they're here for. I tell people all the time, the sites are the windows to the patients. If you wanna know what's going on with the patients, if you want to help understand that experience better, just ask the sites. They're going to advocate for those patients better than anybody else is going to, oftentimes better than the patients themselves. So I think we have an opportunity. We're engaged with these individuals at the sites, and they are, again the individuals that can help us do that.
Jimmy BechtelSo excellent excellent point there. Mike, thank you for being here with us. Thank you for sharing some of the perspective around how we might go about easing some of the burden here and, again, emphasizing points that we make, but also bringing up some really important reminders for us on what we need to do in this space and the approach we need to take when we talk about not only designing, but also executing clinical trials. So again, thank you for being with us here today.
Mike HuttonThank you, Jimmy. It's a pleasure talking to you today.
Jimmy Bechtelthanks again. And for those listening, I also want to make sure that you check out other site-focused resources on our website, myscrs.org, like other podcasts, webinars, and articles and data that we've talked about and produced that speak to this topic specifically around how we can work better together to reduce burden at the site and patient level. But for now, thanks for listening, tuning in, and until next time.
In this episode of SCRS Talks, Mike Wenger, Chief Innovation Officer at CRIO, discusses the opportunities and risks of AI in clinical research. The conversation explores how sites can benefit from AI-driven efficiency...
Clinical research software has rarely been built with sites in mind. Storm Stillman, CEO of SiteBase, by Curebase and one of SCRS’s newest Global Impact Partners, talks about how that’s changing. Storm shares what...
In this episode of SCRS Talks, Jimmy Bechtel sits down with Tom Farrand, Co-Founder and CEO of Delfa, to break down what a healthy recruitment funnel looks like from first inquiry to scheduled visit. Tom shares...
Technology is consistently one of the top pain points for research sites, and a big reason is that sites often aren't part of the conversation until a solution is already built. In this episode of SCRS Talks, Jimmy...
Site engagement often shows up only after a study is already in trouble. In this episode of SCRS Talks, Jimmy Bechtel sits down with Julie Wilhjelm, Senior Director of Site Strategy and Engagement at Novotech, to talk...